Date:1/30/2011

s represent our judgment as of the date of this report. We disclaim, however, any intent or obligation to update our forward-looking statements.CARACO PHARMACEUTICAL LABORATORIES, LTD.(A subsidiary of Sun Pharmaceutical Industries Limited)STATEMENTS OF OPERATIONSNine Months ended December 31,Quarter ended December 31,2010200920102009(UNAUDITED)(UNAUDITED)(UNAUDITED)(UNAUDITED)Net sales $ 268,205,415 $ 178,435,869 $  40,386,809 $  51,989,958 Cost of goods sold245,842,635 7,148,654 37,061,173 48,905,076 Reserve for inventory seized by FDA-   5,950,188 -   -   Gross profit (loss)22,362,780 (4,662,973)3,325,636 3,084,882 Selling, general and administrative expenses20,399,479 5,855,217 ,592,397 5,402,641 Research and development costs7,824,822 8,346,916 ,726,940 2,753,965 Non-recurring (income)-   (20,000,000)-   -   Operating loss(5,861,521)(8,865,106)(4,993,701)(5,071,724)Other income (expense)  Interest expense(397,270)(402,174)(18,645)(144,089)  Interest income,018,552 464,835 85,519 200,175  Gain / (loss) on sale of equipment7,205 (114,272)4,705 -    Other income3,649 20,698 3,649 74,390 Other income – net632,13669,087175,228130,476Loss before income tax benefit(5,229,385)(8,796,019)(4,818,473)(4,941,248)  Income tax benefit(1,896,069)(3,008,190)(1,783,205)(1,907,934)Net loss $   (3,333,316) $   (5,787,829) $   (3,035,268) $   (3,033,314)Net loss per common share  Basic

$(0.08)$(0.15)$(0.08)$(0.08)  Diluted$(0.08)$(0.15)$(0.08)$(0.08)Weighted number of shares  Basic

39,397,22738,457,17639,788,93339,090,194  Diluted

39,397,22738,457,17639,788,93339,090,194
'/>"/>

SOURCE Caraco Pharmaceutical Laboratories, Ltd. Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8
Related medicine technology :

1. Caraco Pharmaceutical Laboratories, Ltd. Provides Update on Remediation Activities
2. Caraco Pharmaceutical Laboratories, Ltd. Announces Extension and Future Termination of Distribution Agreements with Sun Pharma
3. Independent Committee of Caraco Board Retains Independent Advisors for Consideration of Sun Pharma Proposal to Purchase Outstanding Shares and Caraco Acknowledges Filing of Purported Class Action Lawsuits
4. Independent Committee of Caraco Board to Consider Sun Pharma Proposal to Purchase Outstanding Shares
5. Caraco Receives Sun Pharma Proposal to Purchase All Outstanding Shares
6. Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the Second Quarter and First Six Months of Fiscal Year 2011
7. Caraco Pharmaceutical Laboratories, Ltd. Announces Change to Executive Team as G. P. Singh to Assume Position of CEO Effective November 1, 2010 and Update on Remediation Status
8. Caraco Pharmaceutical Laboratories, Ltd. Announces Appointment of Eddie Munson to Board of Directors
9. Caraco Pharmaceutical Laboratories, Ltd. Announces G.P. Singh Sachdeva Is Appointed as Chief Operating Officer
10. Caraco Pharmaceutical Laboratories, Ltd. Markets Generic Flomax®
11. Caraco Pharmaceutical Laboratories, Ltd. Markets Generic Wellbutrin SR® Extended Release Tablets